Orthobiologics Market Update

Thanks to Google Alerts, this article came to my attention…

The article titled “Primary Catalyst Driving Orthobiologics Market Evolution in 2025” discusses the significant growth trajectory of the orthobiologics market. It highlights that the market is projected to expand from $7.08 billion in 2024 to $7.56 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.7%. This growth is attributed to factors such as the increasing incidence of orthopedic diseases, a shift towards less invasive procedures, a rise in reconstructive surgeries, growing healthcare expenditures, heightened awareness among patients and healthcare providers, and economic development in emerging markets.

Looking ahead, the market is expected to reach $9.7 billion by 2029, with a CAGR of 6.5%. Key drivers for this forecasted growth include an aging population, sedentary lifestyles, continuous advancements in product development, supportive reimbursement policies, regulatory approvals for new orthobiologic products, and expanded usage of existing offerings. Emerging trends in the industry encompass progress in regenerative medicine, product innovation, technological advancements, and strategic planning.

A significant catalyst for market expansion is the rising occurrence of road accidents and sports-related injuries, which often result in musculoskeletal damage. Orthobiologic treatments, utilizing materials like bone grafts, growth factors, stem cells, and platelet-rich plasma, are employed to promote quicker and more effective recovery of musculoskeletal tissue, reduce inflammation, and enhance the body’s natural repair mechanisms. For instance, Eurostat reported a 3.7% increase in road accident fatalities in Europe, from 19,917 in 2021 to 20,653 in 2022. This upward trend in injuries underscores the growing demand for orthobiologic treatments.

The article also identifies major companies driving the orthobiologics industry, including Johnson & Johnson, Medtronic plc, Zimmer Biomet, Arthrex Inc., and Integra Lifesciences Corporation. Additionally, it notes that leading corporations are innovating advanced solutions, such as dry allograft mixtures, to enhance bone fusion and recovery in orthopedic surgeries.

In summary, the orthobiologics market is experiencing substantial growth, driven by demographic shifts, technological innovations, and an increasing demand for effective treatments for musculoskeletal injuries.[1]

What do other sources say?

The orthobiologics market is experiencing significant growth, driven by factors such as the increasing prevalence of orthopedic procedures, a growing geriatric population, and advancements in regenerative medicine. In 2023, the global market was valued at approximately USD 6.4 billion and is projected to reach USD 9.3 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.5% during the forecast period.[2]

North America holds a substantial share of the market, accounting for 46.9% of global revenue in 2023. This dominance is attributed to the high number of orthopedic procedures performed in the region and the presence of major industry players.[2]

The market’s expansion is further propelled by the rising incidence of road accidents and sports-related injuries, which increase the demand for effective orthopedic treatments. For instance, in Europe, road accident fatalities increased by 3.7% from 2021 to 2022.

Product innovation plays a crucial role in market growth. Companies are focusing on developing advanced orthobiologic products, such as demineralized bone matrices and stem cell therapies, to enhance treatment outcomes. These innovations aim to improve therapeutic efficacy and reduce recovery times for patients undergoing orthopedic procedures.[3]

Despite the positive outlook, the market faces challenges, including high treatment costs and stringent regulatory frameworks, which may hinder growth. Nevertheless, the ongoing development of advanced products with improved therapeutic efficacy is expected to provide opportunities for market expansion.[3]

In summary, the orthobiologics market is poised for substantial growth, driven by demographic trends, technological advancements, and an increasing demand for effective orthopedic treatments.

References

[1] The Business research company. (2025, February 12). Primary Catalyst driving Orthobiologics market evolution in 2025: Orthobiologics Market Growth Driven by RiSIN. openPR.com. https://www.openpr.com/news/3864488/primary-catalyst-driving-orthobiologics-market-evolution

[2] Orthobiologics Market Size, Share & Trends Analysis Report by product (DBM, Allograft, BMP, Viscosupplementation), by application (Spinal Fusion, trauma Repair), by end-use, by region, and segment Forecasts, 2024 – 2030. (n.d.). https://www.grandviewresearch.com/industry-analysis/orthobiological-products-market

[3] Dighe, K. (2024, April 26). Orthobiologics Market Size, Share, Trends and Forecast 2031. Coherent Market Insights. https://www.coherentmarketinsights.com/market-insight/orthobiologics-market-1306